Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide

被引:34
作者
Webster, LK [1 ]
Linsenmeyer, ME [1 ]
Rischin, D [1 ]
Urch, ME [1 ]
Woodcock, DM [1 ]
Millward, MJ [1 ]
机构
[1] PETER MACCALLUM CANC INST,DIV HAEMATOL & MED ONCOL,MELBOURNE,VIC 3002,AUSTRALIA
关键词
polysorbate; 80; multidrug resistance; docetaxel; etoposide;
D O I
10.1007/s002800050615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Docetaxel (Taxotere, Rhone-Poulenc Rorer) and etoposide are water-insoluble drugs formulated with polysorbate 80 for intravenous administration. We have previously reported that surfactants, including polysorbate 80 and Cremophor EL, can reverse the multidrug resistance (MDR) phenotype in an experimental system and that plasma Cremophor EL concentrations measured following a 3-h infusion of paclitaxel were greater than or equal to 1 mu l/ml, sufficient to modulate MDR in vitro. The purpose of this study was to measure polysorbate 80 plasma concentrations in patients following intravenous administration of etoposide or docetaxel using a bioassay in which MDR-expressing cells are incubated with daunorubicin (DNR) plus 50/50 growth medium/plasma and equilibrium intracellular DNR fluorescence is measured by flow cytometry. In vitro experiments show maximal reversal of MDR at concentrations of 1.0-2.0 mu l/ml and 50% reversal at 0.2-0.3 mu l/ml. Patients received docetaxel at 75 mg/m(2) (five patients) or 100 mg/m(2) (four patients) (total dose 125-178 mg, containing 3.12-4.45 mi polysorbate SO) over 60 min. The median end-infusion polysorbate 80 concentration was 0.1 mu l/ml (range 0.07-0.41 mu l/ml). Only one patient had a level of >0.2 mu l/ml. Five patients received intravenous etoposide at 120 mg/m(2) over 45-120 min (total dose 180-250 mg, containing 0.67-0.93 ml polysorbate 80). In the end-infusion plasma sample, polysorbate 80 was not detectable (<0.06 mu l/ml) in any patient. Plasma polysorbate 80 levels following an intravenous infusion of 120 mg/m(2) etoposide or of docetaxel at doses used in Phase II trials, are insufficient to show modulation of MDR in vitro.
引用
收藏
页码:557 / 560
页数:4
相关论文
共 19 条
[1]  
AZMIN MN, 1985, CANCER CHEMOTH PHARM, V14, P238
[2]  
BOURGEOIS H, 1996, P AN M AM SOC CLIN, V15, P148
[3]   INFLUENCE OF POLYSORBATE-80 (TWEEN-80) AND ETOPOSIDE (VP-16-213) ON THE PHARMACOKINETICS AND URINARY-EXCRETION OF ADRIAMYCIN AND ITS METABOLITES IN CANCER-PATIENTS [J].
CUMMINGS, J ;
FORREST, GJ ;
CUNNINGHAM, D ;
GILCHRIST, NL ;
SOUKOP, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 17 (01) :80-84
[4]   POTENTIATION OF ANTICANCER-DRUG CYTOTOXICITY BY MULTIDRUG-RESISTANCE CHEMOSENSITIZERS INVOLVES ALTERATIONS IN MEMBRANE FLUIDITY LEADING TO INCREASED MEMBRANE-PERMEABILITY [J].
DRORI, S ;
EYTAN, GD ;
ASSARAF, YG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 228 (03) :1020-1029
[5]   REVERSAL OF MULTIDRUG-RESISTANCE PHENOTYPE BY SURFACTANTS - RELATIONSHIP TO MEMBRANE LIPID FLUIDITY [J].
DUDEJA, PK ;
ANDERSON, KM ;
HARRIS, JS ;
BUCKINGHAM, L ;
COON, JS .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 319 (01) :309-315
[6]   Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80 [J].
Ellis, AG ;
Crinis, NA ;
Webster, LK .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (01) :81-87
[7]  
FRICHE E, 1990, CANCER COMMUN, V2, P297
[8]   PACLITAXEL BY 3-HOUR INFUSION IN COMBINATION WITH BOLUS DOXORUBICIN IN WOMEN WITH UNTREATED METASTATIC BREAST-CANCER - HIGH ANTITUMOR EFFICACY AND CARDIAC EFFECTS IN A DOSE-FINDING AND SEQUENCE-FINDING STUDY [J].
GIANNI, L ;
MUNZONE, E ;
CAPRI, G ;
FULFARO, F ;
TARENZI, E ;
VILLANI, F ;
SPREAFICO, C ;
LAFFRANCHI, A ;
CARACENI, A ;
MARTINI, C ;
STEFANELLI, M ;
VALAGUSSA, P ;
BONADONNA, G .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2688-2699
[9]  
GIANNI L, 1995, P AM SOC CLIN ONCOL, V14, P169
[10]  
HARRISON SD, 1984, EUR J CANCER, V17, P387